GSK’s share price looks a steal to me anywhere below £43.29, and here’s why
GSK’s share price has fallen a long way from its one-year high, which has only increased the major undervaluation I'd seen in the stock before that. The post GSK’s share price looks a steal to me ...
DIARIO MEDICO.COM2d
Nuevos respaldos para la británica GSK en ITUs y EPOC
La FDA autoriza el antibacteriano gepotidacina, primero de clase y primero frente a ITUs en 30 años, mientras que la EMA acepta revisar el uso de mepolizumab para añadirle la EPOC. Los compuestos ...
Vademecum.es5d
La Agencia Europea de Medicamentos acepta revisar la solicitud de GSK de ampliar el uso de Nucala (mepolizumab) para el tratamiento de la EPOC
GSK ha anunciado hoy que la Agencia Europea de Medicamentos (EMA) ha aceptado revisar su solicitud de ampliar el uso de ...
Healio6d
Mepolizumab lowers repeat surgery risk for CRSwNP regardless of number of past surgeries
Among patients with previous sinus surgery for chronic rhinosinusitis with nasal polyps, the number of past surgeries did not ...
How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology
After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma ...